31 results about "Diuretic" patented technology

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present technology is generally directed to flow cartridges configured to measure and / or detect analytes in urine. A representative flow cartridge includes a urine inlet configured to receive urine from a patient, a flow channel fluidly coupled to the urine inlet, and sensors fluidly coupled to the flow channel that are configured to measure parameters of the urine flow. The sensors are aligned with corresponding sensing zones of the flow channel and are operable to generate sensor data based on urine flow through the sensing zones. In some embodiment, the sensor data is used to provide fluid therapy to the patient by adjusting an amount or rate of diuretic and / or hydration fluid based on the sensor data.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.

The invention relates to a pet composition for preventing urinary tract calculi and improving urinary tract health and application thereof. The composition for pets comprises a mucosal barrier repairing agent, an antibacterial adhesive, an inflammation regulator, a diuretic and an antioxidant, the antibacterial adhesive comprises a combination of D-mannose and a cranberry extract. The composition for pets provided by the invention can be used for repairing bladder mucosa from multiple dimensions, inhibiting bacteria from adhering to the bladder wall, reducing urinary stones, regulating inflammation and improving urinary tract health.

This present disclosure relates to fluid therapy based on adjusted urine output rate and / or sodium output rate, and associated systems, devices, and methods. Exemplary methods can include receiving a sodium excretion input for the patient; receiving a urine output rate; determining an adjusted urine output rate based on the sodium excretion input and the urine output rate; and providing fluid therapy based on the adjusted urine output rate. By determining the amount and / or rate of the infused diuretic and / or hydration fluid based on a patient's actual sodium excretion levels, embodiments of the present technology can optimize and / or customize all or a subset of a diuretic therapy to an individual patient's physiology.

This article provides a pharmaceutical composition for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

This invention discloses a traditional Chinese medicine composition for assisting in the improvement of hand-foot-mouth disease in infants and young children, belonging to the field of traditional Chinese medicine technology. The composition consists of eight medicinal herbs: lotus leaf, coix seed, angelica dahurica, kudzu root, platycodon root, agastache rugosa, cimicifuga rhizome, and dandelion, with a defined optimal medicinal ratio. Based on the seasonal differences in the pathogenesis of hand-foot-mouth disease, this invention targets the core pathologies of winter (cold congestion of microvessels, water and sodium retention, and internal heat generation) and spring and summer (hypothalamic sympathetic activation, increased heart rate, and visceral heat overload). It also addresses the technical deficiencies of clinical Western medicine, cold-natured traditional Chinese medicine, calamine lotion, and diuretics, such as vasoconstriction, kidney damage, central nervous system disorders, increased skin exudation, and rebound water retention. This invention employs a combination of warming and cooling herbs, regulating the ascending and descending functions, and promoting diuresis and protecting the body's vital energy. The synergistic effects of these herbs can dilate spasmodic microvessels, improve renal perfusion, stabilize abnormal heart rates, stabilize the hypothalamic center, and assist in antagonizing enteroviruses. By targeting and reducing abnormal permeability of skin capillaries with Angelica dahurica and Platycodon grandiflorus, it reduces blood extravasation and inhibits the formation and exudation of herpes from the root cause. This invention has mild medicinal properties, is suitable for all seasons, and has high safety. It can effectively improve symptoms of hand-foot-mouth disease such as fever, herpes, irritability, and cold extremities, reduce the risk of severe illness, antagonize the toxic side effects of commonly used clinical drugs, and is suitable for the delicate constitution of infants and young children, possessing good prospects for clinical application and promotion.

Methods for controlling fluid management for a patient are disclosed herein. An example computer-implemented method comprises: initializing a fuzzy machine learning model based on a fluid management ruleset for a population including the patient; training the fuzzy machine learning model on historical medical data associated with the population to generate a trained fuzzy ruleset, the historical medical data including a plurality of indications of historical fluid management treatments for the population and associated treatment outcomes; receiving clinical data for the patient; generating a fluid management recommendation by applying the trained fuzzy ruleset to the clinical data for the patient; presenting, via a graphical user interface, the fluid management recommendation and one or more indications of corresponding rales included in the trained fuzzy ruleset to a clinician.

Materials and methods for treating hypertension (including resistant hypertension) with a combination of an M-atrial natriuretic peptide (MANP) and a diuretic agent (e.g., furosemide) are described herein.

Embodiments of the present technology can manage a patient's fluid removal based on one or more of the patient's urination, urinary conductivity, urinary sodium concentration, and / or urinary oxygen content. For example, in some embodiments, the patient's urinary sodium concentration (and / or an indication thereof, including, for example, the patient's urinary conductivity) can be compared to one or more urinary sodium concentration thresholds (e.g., a high urinary sodium concentration threshold and / or a low urinary sodium concentration threshold) to determine one or more adjustments to the patient's therapy, such as, for example, diuretic administration rate, hydration fluid infusion rate, hydration fluid compatibility percentage, etc. Additionally or alternatively, the patient's urinary oxygen content can be compared to one or more urinary oxygen content thresholds (e.g., a high urinary oxygen content threshold and / or a low urinary oxygen content threshold) to determine one or more adjustments to the patient's therapy.

This invention provides a method of treating hypertension in a hypertensive subject, the method administering to the subject, an amount of a diuretic and an amount of a CYP 11β2 beta hydroxylase inhibitor once or twice per day, wherein the amounts taken together are sufficient to treat hypertension in the hypertensive subject when taken in combination with other antihypertensive agents. In particular, the method is sufficient to elicit a safe and robust reduction in hypertension (>10 mmHg reduction in systolic blood pressure) in the hypertensive subject.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a traditional Chinese medicine preparation for treating heart failure and diuretic resistance and a preparation method of the traditional Chinese medicine preparation. The active extract is prepared from the following raw material medicines: astragalus membranaceus, ginseng, cinnamon, salvia miltiorrhiza, red paeony root, radix rehmanniae recen, cassia twig, ligusticum wallichii and pseudo-ginseng. On the basis of a traditional qi-tonifying and blood-activating treatment method, a treatment method for enhancing the effect of dredging collaterals and the effect of nourishing yin is combined, the cinnamon serves as a core monarch drug to warm and tonify yang of the heart and the kidney, and compatibility is scientific; the cortex cinnamomi is used for completely replacing radix aconiti lateralis preparata, so that potential cardiotoxicity and neurotoxicity risks caused by aconitum alkaloids are fundamentally eliminated; the traditional Chinese medicine preparation disclosed by the invention provides a solid guarantee for long-term and safe medication of patients with heart failure, is more suitable for treating intractable and complicated heart failure, and has a good clinical application value.

The present invention relates to an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment that binds to adrenomedullin, for use in congestion therapy in a patient with congestive hypertension; heart failure, in particular acute heart failure; wherein said anti-ADM antibody or anti-ADM fragment binds to the N-terminal portion (aa 1 to 21) of adrenomedullin YRWSMNNFWGLRSFGCRFGTC (SEA ID NO. 22), and wherein said patient is resistant to diuretics or does not respond to diuretic therapy.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

The present invention relates to the technical field of biomedicine, and in particular to a sulfonamide compound for therapeutic use, an enantiomer thereof, a preparation method, and uses. The present invention provides the following beneficial effects: the provided sulfonamide compound and the enantiomer thereof have the characteristics of high stability, a prolonged duration of action, superior efficacy, and the like, thereby serving as a superior diuretic and a novel anti-cerebral edema drug.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Use of a pyridine sulfonamide phosphate compound or a pharmaceutical composition comprising the same in the preparation of a drug for treating pulmonary edema. This drug inhibits the NKCC1 target in the lungs through a novel mechanism of action, demonstrating outstanding efficacy in treating pulmonary edema with high safety. It can significantly reduce drug distribution in kidney tissue, thereby reducing adverse effects such as electrolyte disturbances caused by potent diuretics. It holds promise as a novel drug for the clinical treatment of pulmonary edema and has a very broad clinical application prospect.

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

The application discloses a kind of prediction method for fluid volume status and diuretic resistance state of heart failure patient, it is related to medical instrument and diagnostic technical field. Including: collecting the original data of heart failure patient;Original data is carried out data preprocessing;The original data after preprocessing is input into the fluid volume assessment model of heart failure patient, according to the data index of heart failure patient, two categories are distinguished: fluid volume is insufficient and fluid volume is not insufficient;Heart failure patient of fluid volume is insufficient, directly output diagnosis result and corresponding visit suggestion;Fluid volume is not insufficient for heart failure patient, carries out diuretic resistance detection;The data index of heart failure patient is input into the diuretic resistance identification model of heart failure patient, according to the data index of heart failure patient, two categories are distinguished: diuretic resistance and diuretic non-resistance;Finally, output diagnosis result and corresponding visit suggestion.The application can predict the fluid volume status and diuretic resistance state of patient in real time and accurately.

Methods for controlling fluid management for a patient are disclosed herein. An example computer-implemented method comprises: initializing a fuzzy machine learning model based on a fluid management ruleset for a population including the patient; training the fuzzy machine learning model on historical medical data associated with the population to generate a trained fuzzy ruleset, the historical medical data including a plurality of indications of historical fluid management treatments for the population and associated treatment outcomes; receiving clinical data for the patient; generating a fluid management recommendation by applying the trained fuzzy ruleset to the clinical data for the patient; presenting, via a graphical user interface, the fluid management recommendation and one or more indications of corresponding rules included in the trained fuzzy ruleset to a clinician.

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The invention relates to the technical field of traditional Chinese medicine compound preparations, and discloses a pharmaceutical composition and application thereof in preparation of drugs for preventing and treating hyperuricemia and gout, the pharmaceutical composition takes gentiana macrophylla as a monarch material, and focuses on expelling wind-damp, clearing damp-heat, relieving arthralgia, inhibiting uric acid generation, and promoting kidney excretion to reduce blood uric acid. Gastrodia elata and radix cyathulae serve as ministerial drugs, and gastrodia elata dispels wind, dredges collaterals The radix cyathulae has the effects of easing joint movement, guiding the medicine to move downwards and inducing And the raw lalang grass rhizome is used for reducing fever and causing diuresis, and guiding turbidity to go out. Ligusticum wallichii is used as a guide to activate blood and qi, dispel wind and relieve pain. Through targeted adjustment of the ratio of the raw materials and scientific compatibility, the effects of reducing the level of serum uric acid, remarkably improving the activity of liver uricase, synchronously improving renal function indexes, relieving hepatic and nephropathy damage, resisting acute gout and the like are achieved, and the medicine effect is remarkable.

The present invention provides a method of treating hypertension in a hypertensive subject, the method comprising administering to the subject an amount of an angiotensin II receptor blocker (ARB), an amount of a thiazine-based or thiazine-like diuretic agent once a day, and an amount of lorenstat or a pharmaceutically acceptable salt thereof once a day, wherein these amounts taken together are sufficient to treat hypertension in the hypertensive subject.

The invention is applicable to the technical field of biomedicine, relates to a construction method and application of a diuretic-resistant cell model, and establishes the diuretic-resistant cell model by using angiotensin II and aldosterone to jointly induce mouse renal manifold M-1 cells. The model is verified by detecting gene and protein expression levels of aquaporin 2, epithelial sodium channel alpha subunit and arginine vasopressin receptor 2. The method is simple to construct and good in repeatability, can truly reflect the pathological characteristics of diuretic resistance, can stably simulate the state of water-sodium retention caused by excessive activation of a renin-angiotensin-aldosterone system, can reproduce the core characteristic of insufficient curative effect of the diuretic, verifies the occurrence effect of the diuretic resistance, and has a good application prospect. And a stable and controllable in-vitro model is provided for researching a molecular mechanism of diuretic resistance and screening prevention and treatment drugs.

The present invention provides a composition for treating edema unresponsive to oral diuretics. [Solution] A pharmaceutical composition is provided comprising (i) an aqueous solution having a pH of about 5 to about 9, (ii) a bumetanide potassium salt in a concentration of about 4 mg / mL to about 20 mg / mL, and (iii) one or more pharmaceutically acceptable excipients.

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.